Department o f P e d i a t r i c s , U n i v e r s i t y of Bologna. I t a l y .
GH-RF d e f i c i e n t c h i l d r e n (1 u i t h i s o l a t e d GH-deficiency, 2 u i t h GH-TSH d e f i c i e n c i e s , 1 u i t h GH-TSH-ACTH-deficiencies) u e r e a d m i n i s t e r e d 5.c. hGH ( a f t e r t h e p r e v i o u s hGH t r e a t m e n t had been d i s c o n t i n u e d 1 week before the s t u d y ) a t a dose o f 0.1 UI/Kg. according t o u s u a l s u b s t i t u t i v e therapy. a t t i m e s 0 and 48 h.

A f t e r a f u r t h e r week n i t h o u t t h e r a p y the s u b j e c t s u e r e a d m i n i s t e r e d i . v . GH-RF a t a dose o f 3 )g/Kg a t t i m e s
h
. SmC b l o o d samples u e r e c o l l e c t e d a t time 0 and, a f t e r hGH and GH-RF a d m i n i s t r a t i o n s , a t t i m e s
4. 8,12.16.24,28,32,36,40,48,52,56.50,64,72 h. I n a l l p a t i e n t s a s i g n i f i c a n t GH-response ( 4 n g / a l ) uas a t t a i n e d a f t e r each GH-RF a d m i n i s t r a t i o n . I n 3 s u b j e c t s a SnC i n c r e a s e was observed a f t e r both hGH and GH-RF a d m i n i s t r a t i o n s .
I n 1 case t h e r e u e r e no changes i n SnC l e v e l s a f t e r both hGH and GH-RF a d m i n i s t r a t i o n s . By c a l c u l a t i n g the i n t e g r a t e d areas of the SmC curve. t h e values o b t a i n e d a f t e r hGH and GH-RF a d m i n i s t r a t i o n s u e r e h i g h e r i n 2 cases a f t e r t h e GH-RF i n j e c t i o n . h i g h e r i n 1 case a f t e r the hGH i n j e c t i o n , and i n 1 case t h e areas were s i m i l a r . I n our p a t i e n t s and i n our experimental -So far 51 children were tested in an identical mode. In the 32 cases classified as non-3 deficient all GH levels rose to more than 8 ng/ml (1. IRP) above basal with trends according to sex and age. In 19 cases GHD had been established by testing with insulln and arginine, and Sm measurements. In these patients GH increments were: <3 ng/ml in 10, 3-5 ng/ml in 6, and >9 ng/ml (14.6, 9.1, 35.8) in 3 cases. Thus, GRF(~-29) is suitable for GH testing. Easier synthesis rakes it also appear to be a favourable alternative for attempts to treat hypothalamic gravth hormone deficiency. he^ long term effect of-daily injeGions of GFS (1 ug/kg bw,sc) was studied in developing male rats.In tm additional groups GRF was stopped on day 30 and on day 50.Weight and length were m asured at 5 days intervals,GH and somtomedin =re ~asured at diverse t W pints by RIA.When cqared to the controls,GRF treated animals did not differ in length at the end of the observation pericd(day 75) .On the other hand,the growth pattern was markedly different.GRF treated animals grew faster f r m day 15 to day 25,and had significantly lower GH levels than the controls on day 30 (3.05 vs 23.0112 ng/ml,p<O.Ol) .Grawth velccity in the GRF group decreased slightly until day 45,on which e mrirwntal and control group did not differ any m r e in 1ength.m the contrary,a significant catch up in length (p<0.001) ,follo& by a decrease in growth velocity was observed when GRF was stopped on day 30,final length not differing from the controls.This pattern was not observed. when treatment was stopped on day 50.0n the other hand,a significant and lasting increase in wight was observed after GRF withdrawal in both groups.These animals =re on day 75 significantly heavier than the chronically treated and the controls(286+16 and 287~8 vs 27227 and 264212 gr,p<O.O5).The results indicate that chronic GRF administration might alter GH secretion possibly by down regulation of pituitary receptors, and affects the pubertal growth pattern,but not the final length.
EFFECT OF CHRONIC GRF
THE EFFECT OF WEANING AND MATERNAL SEPARATION UPON GROWTH HORMONE RESPONSE TO GROWTH HORMONE RELEASING
48 FACTOR I N THE INFANT RHESUS MONKEY. J u l i e t Singh, Linda Falloon, and Dennis Styne. Department o f P e d i a t r i c s , Univ e r s i t y 07 C a l i f o r n i a , Davis, CA USA.
Human i n f a n t s w i t h t h e maternal d e p r i v a t i o n syndrome have poor growth and e l e v a t e d plasma growth hormone (GH) c o n c e n t r a t i o n s which have been a s c r i b e d t o e i t h e r psychological f a c t o r s o r inadequate c a l o r i c i n t a k e . I n f a n t Rhesus monkeys were s t u d i e d as a p o t e n t i a l model o f t h e psychological o r n u t r i t i o n a l e f f e c t s o f weaning and maternal separation upon t h e GH response t o growth hormone r e l e a s i n g f a c t o r (GHRF). A f t e r 60 rnin o f e q u i l i b r a t i o n , s i x 3-month o l d monkeys a t t h e C a l i f o r n i a Primate Research
Center were g i v e n 10 mcg/kg o f GHRF i n t r a v e n o u s l y and sera was analyzed f o r GH by radioimmunoassay a t - 30,-15,0,7,15,30,60 and 120 rnin. The i n f a n t s were then weaned from t h e i r mothers and housed i n nursery observation cages and 7 days l a t e r t h e GHRF s t u d y was repeated. Two animals had no change i n peak GH values a f t e r weaning, w h i l e t h e o t h e r f o u r had a s i g n i f i c a n t i n c r e a s e i n peak GH and r i s e i n GH a f t e r GHRF (mean 5 SD).
Basal GH
Peak GH D e l t a GH weaning: pre p o s t p r e p o s t p r e p o s t 4.1A1.5 5 . 4 3 . 9 7.150.84 24.556.6 3.022.2 1 9 . 1 5 . 5 n o n -s i g n i f i c a n t p<. 001 p<.OOl The changes were u n r e l a t e d t o n u t r i t i o n a l d e p r i v a t i o n as a l l a n imals were e a t i n g n o r m a l l y and g a i n i n g weight by t h e second s t u d y . The weanling Rhesus monkey may r e f l e c t t h e e a r l y endocrine changes o f maternal d e p r i v a t i o n i n c h i l d r e n .
INSULIN-LIKE GROWTH FACTOR(1GF)AND CARRIER PROTEIN SERUM LEVELS IN TALL GIRLS ON HIGH-
49 DOSE ESTROGENS. Udo Heinrich,Klaus Hartmann, Monica Muller,Ingrid Fehres and Dieter Schonberg,Universitats-Kinderklinik,Heidelberg,FRG.
To further elucidate the behavior of IGF under higF,-dose estrogens we have determined total IGF (tIGF) by a competitive protein binding assay,IGF-I by RIA and IGF carrier protein levels by a modification of the protein binding assay in 17 excessively tall girls (mean age + SD:13.9 2 1.3 yrs, mean bone age 2 SD:12.4 +0.6 yrs)before and 12 months after initiation of -estrogen treatment (ethinylestradiol (EE) 300 pg per day).
Before therapy the mean + SD serum level of tIGF was 427 + 43.4 pU/ml,of IGF-I 182.9 236.4 ng/ml.tIGF decreased to 370.7 + 72 uU/m1(86% of level before),IGF-I to 128.3 + 19.3 ng/ml(70% of level before).Carrler protein concentrations did not change significantly(430.3 c58.4 ngeq/ml vs. 415.9 2 77.5 ngeq/ml,n.s.)There was -a significant positive correlation between IGF-I and growth rate(r=0.55,p<0.05) and a significant negative correlation between AIGF-I and growth rate(r=0.66. p<0.001) on CE.-Our results are in keeplng with the assumption that growth inhibition observed with highdose estrogens is at least in part due to a speclfic effect on IGF production.While the net carrler protein content is unchanged, the possibility has to be tested that IGF metabolism may be increased by a change of the carrler protein composition. In subjects with various growth rates (without any clinical or biological abnormalities) IGF I related peptides increase with age in a similar way but at different levels. In comparison with normal subjects (height = mean for age & 1 SD), IGf levels measured by competitive protein-binding assay were found significantly higher in subjects with tall stature (height > mean for age + 2 SD) and significantly lower in subjects with short stature (height < mean for age -2 SD). Analysis of the data altogether shows that 1) the positive correlation between IGF and height (r : 0.71, p < 0.001, n 227) does exist without respect to age, as shown when studying the ratios of height/normal height for age vs IGF/normal IGF for age ( r = 0.61., p < 0.001); 2) in subjects whose growth was followed up (tall and short stature) a positive correlation is found between the ratios of growth velocity (gv)/normal gv for age and IGF/normal IGF for age (r : 0.52, p < 0.001, n = 111). The differences in IGF levels between the three groups of subjects (which contrast with no differences in GH levels in the usual pharmacological tests) disappear after epiphyseal fusion. These results suggest that, during growth, individual differences in height and growth velocity seem to be directly related to the IGF secretory capacity. This provides further evidence for an important r81e or IGF I in the physiological control of growth.
BODY SIZE AND GROWTH VELOCITY PARALLEL INSULIN-LIKE
